Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia

Hong-Xia Peng 1, Xiao-Dan Liu 2, Zi-Yan Luo 1, Xiao-Hong Zhang 1, Xue-Qun Luo 3, Xiao Chen 4, Hua Jiang 1* and Ling Xu 1*

Abstract

Background: Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied.

Methods: The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan–Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated.

Results: Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a.

Conclusions: Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.

Keywords: Bmi-1, Pediatric acute lymphoblastic leukemia, Sall4, Prognosis

Background

Acute lymphoblastic leukemia (ALL) is a common pediatric malignant tumor characterized by the overproduction and accumulation of immature lymphoid cells and accounts for nearly 25% of all cancers among children younger than 15 years old [1]. Although treatment options for ALL have significantly expanded in the last 10 years, 15–20% of ALL patients cannot achieve long-term remission, and relapse remains a challenge in treating pediatric ALL. Therefore, identifying novel prognostic markers is an urgent issue in ALL [2, 3].

The Bmi-1 (B cell-specific moloney murine leukemia virus integration site 1) gene is a recognized oncogene of the Polycomb-group (PcG) family and was originally identified via retroviral insertional mutagenesis in Eμ-c-myc transgenic mice that were infected with the Moloney murine leukemia virus [4, 5]. The human Bmi-1 gene is located at chr.10p13, which has been shown to undergo rearrangements in malignant T cell lymphomas and chromosomal translocation in infant leukemia [6–8]. Bmi-1 has been implicated to play a critical role in a number of biological pathways, including stem cell self-renewal...
[9–11], DNA damage response [12, 13], cell cycle [14] and senescence [15, 16].

Recently, Bmi-1 has been the focus of significant clinical interest because studies have demonstrated its upregulation in various malignancies such as non-small cell lung cancer [17], breast cancer [18, 19] and colorectal cancer [20], as well as hematological malignancies including mantle cell lymphoma [21], B cell non-Hodgkin’s lymphoma [22] and acute myeloid leukemia (AML) [23]. Abnormal overexpression of Bmi-1 has also been proposed to be involved in tumor invasion, metastasis, cancer therapy failure, and poor prognosis. For example, elevated Bmi-1 levels were observed in 38.7% (29/75) cases in nasopharyngeal carcinoma, and its overexpression is correlated to the patients’ survival rate: the 5-year overall survival rate was higher in the Bmi-1-negative group than that in the Bmi-1-positive group (84.2% vs. 47.6%) [24]. Similar results were also observed in prostate cancer [25, 26], chronic myeloid leukemia [27, 28] and diffuse large B cell lymphomas [29]. Although a relationship between Bmi-1 expression and the prognosis of patients with pediatric ALL has not been determined, the biological functions of Bmi-1 suggest that this protein could play a crucial role in the pathogenesis of pediatric ALL.

In consideration of the important role of Bmi-1 expression in tumorigenesis, the regulation of Bmi-1 is also thought to be essential. Some studies have revealed that Sall4 directly regulates Bmi-1 in both mouse models and human AML cell lines [30, 31]. Consistent with this, a positive correlation between the expression of the Bmi-1 and Sall4 genes was also discovered in the placenta and umbilical cord blood groups [32]. However, to the best of our knowledge, there are no data describing whether Sall4 contributes to the pathogenesis of leukemia.

The current study analyzed the expression and prognostic value of Bmi-1 in pediatric ALL and further elucidated the relationship between Bmi-1 and Sall4. Our results indicated that Bmi-1 was frequently upregulated in patients with ALL compared to healthy subjects, and patients with upregulated Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate than patients who had lower Bmi-1 expression. In addition, Bmi-1 was observed to be positively correlated to Sall4a. Our data suggest that Bmi-1 could serve as a novel biomarker for the prognostic evaluation of patients with pediatric ALL.

Methods

Patients and samples

Tissue samples from 85 ALL patients before initiation of therapy, 19 ALL patients after therapy completion and 18 healthy subjects were collected between July 2006 and June 2009 at the Guangzhou Women and Children’s Medical Center of Guangzhou Medical University and the First Affiliated Hospital of Sun Yat-sen University. The demographics of the patients and healthy donors are summarized in the supplementary data (Additional file 1: Table S1 and Additional file 2: Table S2). Bone marrow was collected from the patients via bone marrow puncture either at the time of diagnosis or during follow-up after treatment. The research protocols were approved by the Ethics Committee of Guangzhou Women and Children’s Medical Center and the First Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from the participants’ parents or guardians.

RNA isolation and quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted from patient samples by using TRIzol reagent (Life Technologies, Grand Island, NY) according to the manufacturer’s protocol. The purity and integrity of total RNA were tested to assess the RNA quality. First, the OD ratios at A260/A280 and A260/A230 ranged between 1.8-2; second, the ratio of the 28S and 18S rRNA bands, which were assessed by denaturing gel electrophoresis, was approximately 2:1. For qRT-PCR, cDNA was synthesized from 100 ng total RNA using ABI TaqMan® Reverse Transcription Reagents (Thermo Fisher Scientific Inc., Waltham, MA USA). For first-strand cDNA synthesis, 100 ng of total RNA was used with random hexamer primers, 1× TaqMan RT buffer, 50 U of MultiScribe Reverse Transcriptase and 40 U of RNase inhibitor in a final volume of 20 μl. The mixture was incubated for 10 min at 25 °C, 30 min at 48 °C, and 5 min at 95 °C. Then, qPCR was performed using a Platinum® Quantitative PCR SuperMix-UDG kit (Thermo Fisher Scientific Inc.) according to the standard TaqMan® protocol. The qPCR was performed in a 20 μl PCR reaction containing 1 μl RT product, 1× PCR SuperMix-UDG, and 100 nM probe. The reactions were performed in a 96-well plate with an initial denaturation at 95 °C for 2 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. All PCR reactions were run in triplicate with GAPDH used as an internal control. All the primers used are listed in Additional file 3: Table S3. The relative expression of each gene was calculated according to the comparative 2−ΔΔCt method where ΔCt = Ct (target gene) – Ct (GAPDH) and ΔΔCt = ΔCt (sample) – ΔCt (control); the processed data are presented as the fold change of each mRNA.

Statistical analysis

All results were analyzed using proper statistical methods. Beyond the traditional descriptive statistical analyses, inferential analyses were performed using nonparametric methods. Differences in the mRNA expression between two groups (e.g., control vs primary, primary vs complete remission (CR), CR vs relapse) were analyzed using the Mann–Whitney U test for independent unpaired samples.
and the Wilcoxon test for paired samples. In instances of comparisons among more than two groups (e.g., samples divided into the low-risk group (LR), intermediate risk group (IR) and high-risk group (HR)), the Kruskal-Wallis test was performed first followed by Bonferroni’s correction for multiple comparisons. For categorical variables, the $\chi^2$ or Fisher exact tests were used, and correlations were determined using the Spearman rank correlation coefficient ($r$). An analysis of RFS—defined as the time from CR to relapse—was performed according to the Kaplan–Meier method, and comparisons of outcomes among subgroups were performed by using the log-rank test. A two-sided $P < 0.05$ was considered to represent a statistically significant difference. All calculations were performed using GraphPad Prism 6.0 software.

**Results**

**Analysis of Bmi-1 expression levels in pediatric ALL patients**

To determine the expression pattern of Bmi-1 in pediatric ALL, 85 bone marrow specimens from pediatric patients with primary ALL and 18 bone marrow specimens from normal subjects were analyzed by using qRT-PCR. Bmi-1 expression was detected in all of the bone marrow samples, with significantly higher expression observed in the primary ALL samples compared with that in the samples from healthy donors ($P < 0.001$, Fig. 1a). Among the 85 ALL samples, 56 (65.9%) cases showed greater than 2-fold upregulation in Bmi-1 expression. To study the changes in Bmi-1 expression before and after therapy treatment, we detected the Bmi-1 levels in pairs of samples from individuals who achieve CR after treatment ($n = 19$). Interestingly, the results found that Bmi-1 expression was sharply decreased in the majority of CR samples (73.7%) after treatment, suggesting that Bmi-1 could be a prognostic indicator (Fig. 1b, $P = 0.0446$). It is noted that the Bmi-1 expression level was still higher than that in normal control subjects although the induction therapy inhibited its expression in these patients to some extent (Additional file 4: Figure S1, $P = 0.0026$). In addition, we assessed several samples by using Western blot. The preliminary data showed that the protein expression levels of Bmi-1 were higher in primary ALL samples than those in the control samples, and Bmi-1 protein expression was slightly decreased in ALL patients who achieved CR, which was consistent with the mRNA expression pattern (data not shown). Therefore, the significant difference in Bmi-1 expression between primary ALL patients and patients who achieved CR implied that Bmi-1 could be used as an important biomarker for clinical prognosis.

**Relationship between Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients**

To determine whether Bmi-1 expression correlates with the clinicopathological characteristics of pediatric ALL patients, we divided the patients into high and low groups based on the median value of Bmi-1 expression among the cohort. Notably, highly expressed Bmi-1 was found to be closely correlated to a poor response to prednisone ($p = 0.039$) and was significantly more prevalent among clinically higher risk groups ($p = 0.002$) (Table 1). To further detect the expression level of Bmi-1 in different clinical risk grade groups, all patients were divided into three hierarchy subgroups (LR, IR, and HR) according to their clinical information (e.g., patient age, initial leukocyte count, patient response to therapy, etc.).
chromosomal aberrations, immunophenotype, minimal residual disease and responsiveness to chemotherapy) as described in Yeoh AE et al. [33] and the CCLG-ALL-2008 protocol [34]. The results showed that Bmi-1 expression exhibited an incremental trend in pediatric ALL patients that corresponded to the clinic risk grades: Bmi-1 showed the highest expression in the HR group followed by the IR group and the LR group (Fig. 2, \( P < 0.001 \)). Compared with that in the LR group, the Bmi-1 expression was approximately 3-fold higher in the IR group and almost 8-fold higher in the HR group. However, there were no correlations between Bmi-1 expression and other available pathological data, including gender, age, white blood cell count (WBC), FAB classification and BCR/ABL fusion gene.

The influence of Bmi-1 expression on the prognosis of pediatric ALL

Of the 85 initially enrolled patients, 14 patients (16.5%) abandoned treatment after diagnosis, and 4 patients (4.7%) received hematopoietic stem cell transplantation and then ceased contact. The remaining 67 pediatric ALL patients (78.8%) received substantially distinct therapies utilizing the IC-BFM 2002 or VHR-ALL GZCLG protocols according to their clinical risk classification after diagnosis. (The details of treatment regimens were available in Additional file 5: Table S4.) The characteristics of the analyzed pediatric ALL subgroups are listed in Additional file 6: Table S5. Compared with those lost to the follow-up, the analyzed subgroup (treatment group) showed no differences in the distribution of the available parameters (e.g., gender, age, WBC count, FAB classification and BCR/ABL fusion gene). After a median follow-up of 17 months (range from 4 to 42 months), the 3-year RFS was 85.1%. In addition, 10 patients (14.9%) relapsed: 7 patients (10.4%) with isolated BM relapse, 2 patients (3%) with isolated central nervous system relapse, and 1 patient (1.5%) with testicular and BM relapse. The remaining 57 patients were in continuous CR.

After conducting a follow-up with these patients, we found that the Bmi-1 expression in the patients who relapsed (\( n = 10 \)) was nearly 5-fold higher at the time of diagnosis than that of the remaining 57 patients with continuous CR (\( P < 0.001 \), Fig. 3a). The results indicated that Bmi-1 expression was related to leukemia relapse; thus, we hypothesized that Bmi-1 could act as a biomarker for predicting leukemia relapse. To confirm it, we detected the expression level of Bmi-1 in 57 newly diagnosed pediatric ALL patients using the same methods described above and found that the levels of Bmi-1 at the time of diagnosis were correlated to RFS. When the full set of 57 samples were divided into different expression groups, we observed that

| Characteristics | \( n \) | Low expression | High expression | \( P \) value |
|-----------------|------|---------------|----------------|-------------|
| Age at diagnosis, y | | | | 0.100 |
| < 6 | 43 | 30 (69.8%) | 13 (30.2%) | |
| \( \geq 6 \) | 42 | 22 (52.4%) | 20 (47.6%) | |
| Gender | | | | 0.161 |
| Male | 60 | 26 (43.3%) | 34 (56.7%) | |
| Female | 25 | 15 (60%) | 10 (40%) | |
| WBC count (\( \times 10^9/\text{L} \)) | | | | 0.153 |
| < 50 | 53 | 30 (56.6%) | 23 (43.4%) | |
| \( \geq 50 \) | 32 | 13 (40.6%) | 19 (59.4%) | |
| FAB classification | | | | 0.315\(^a\) |
| L1 | 34 | 13 (38.2%) | 21 (61.8%) | |
| L2 | 47 | 26 (55.3%) | 21 (44.6%) | |
| L3 | 4 | 2 (50%) | 2 (50%) | |
| Immunophenotype | | | | 0.281\(^d\) |
| T | 11 | 4 (36.4%) | 7 (63.6%) | |
| B | 66 | 39 (59%) | 27 (41%) | |
| BCR/ABL | | | | 0.329\(^d\) |
| + | 8 | 3 (37.5%) | 5 (62.5%) | |
| - | 64 | 40 (62.5%) | 24 (37.5%) | |
| Prednisone-test | | | | 0.039 |
| PGR | 61 | 36 (59%) | 25 (41%) | |
| PPR | 14 | 4 (28.6%) | 10 (71.4%) | |
| Risk group | | | | 0.002\(^d\) |
| LR | 16 | 14 (87.5%) | 2 (12.5%) | |
| IR | 31 | 16 (51.6%) | 15 (48.4%) | |
| HR | 31 | 10 (32.3%) | 21 (67.7%) | |

\(^a\)Two-sided Fisher’s exact test

Table 1 Relationship characteristics of pediatric ALL and Bmi-1 expression level

**Fig. 2** Expression of Bmi-1 mRNA in the low-, intermediate and high-risk groups. \( ***P < 0.001 \), LR, low-risk group; IR, intermediate risk group and HR, high-risk group
patients with Bmi-1 high-expressed at the time diagnosis had a lower RFS rate (75.8%) than patients with low expression of Bmi-1, who had an RFS rate of 94.1% (Fig. 3b).

Elevated expression of Bmi-1 in pediatric ALL is associated with the expression of Sall4a

It was previously reported that there was a significant relationship between the expression of Sall4 and Bmi-1 in AML samples. Based on this evidence, we measured the mRNA levels of Sall4 in pediatric ALL specimens and normal control tissues with the goal of identifying the possible mechanism that causes overexpression of Bmi-1 in ALL. We observed a significantly positive correlation between Bmi-1 expression and Sall4 (Fig. 4a, 2-tailed Spearman’s correlation, r = 0.2707; P = 0.0122); however, there was no statistical correlation between the Sall4b and Bmi-1 expression levels in the ALL samples examined (Fig. 4b, 2-tailed Spearman’s correlation, r = 0.09686; P = 0.3778). Furthermore, we found that there was no significant difference regarding the expression of Sall4a and Sall4b between pediatric ALL and normal control samples. In addition, there was also no difference between primary and CR groups (Additional file 7: Figure S2).

Discussion

New biomarkers could be helpful in predicting treatment outcomes earlier and more precisely, which is of great interest to physicians and researchers in the field. This report describes for the first time that the proto-oncogene Bmi-1 is aberrantly expressed in the majority of primary ALL patients, and this expression is sharply decreased in CR patients after therapy. It has been shown that patients with elevated Bmi-1 expression at the time of diagnosis possessed a significantly higher likelihood of a poor response to prednisone and a higher clinical risk classification. Furthermore, we found that ectopic expression of Bmi-1 was closely associated with a poor prognosis for ALL patient survival, as patients with increased Bmi-1 expression had a significantly lower OS. Thus, this study not only extends our knowledge about the upregulation of this PcG protein but also verifies that Bmi-1 is an important and promising candidate tumor biomarker to predict the prognosis of pediatric patients with ALL.

There have been many studies that investigated the prognostic value of Bmi-1 expression in other types of tumors. Consistent with our results, research on ovarian cancer [35], breast cancer [36, 37], clear cell renal cancer [38], laryngeal carcinoma [39], cervical cancer [40], and esophageal adenocarcinoma [41] have reported an association between high Bmi-1 expression and an unfavorable prognosis. It has also been reported that high expression of Bmi-1 in AML cells is associated with an unfavorable prognosis [42]. In brief, Bmi-1 is at an important lynchpin in more than ten different types of cancer, and a wide spectrum of malignancies implicate Bmi-1 as a suitable candidate for predicting outcomes.

However, Teruyuki et al. [43] reported that Bmi-1 gene expression was lower in pediatric ALL and that there were no significant correlations between the Bmi-1 gene expression level in leukemic cells and clinical characteristics such as patient prognosis. These results were inconsistent with those of our study, which may be due to the different leukemia subtype and the limited number of samples. In Teruyuki’s study, the bone marrow-derived cells were obtained from 15 patients with pediatric precursor B-ALL that were sorted into different subsets by FACS, and CD19+ cells were treated as normal B cells for the analysis. In our study, we used mononuclear cells from the bone marrow instead of sorted normal B cells.

It has been well established that Bmi-1 is an essential regulator of cellular senescence [16, 44] and that overexpression of Bmi-1 could prevent the development of
senescence in proliferating cells by directly repressing the expression of \( p16^{INK4a} \) and \( p19^{ARF} \) [45]. Glucocorticoids then play a major role in apoptosis of hematopoietic cells including lymphocytes [46], exposure to the glucocorticoid dexamethasone results in changes to the expression of genes associated with cellular senescence, for example, upregulating cell cycle-related genes \( p16 \) and \( p21 \) [47]. Therefore, it is conceivable that \( Bmi-1 \) expression in ALL might counteract the effects of glucocorticoids on the cellular senescence pathway. Consequently, this could also explain why ALL patients with high \( Bmi-1 \) expression exhibited a poor response to prednisone.

Furthermore, our results also demonstrated that \( Sall4a \) and \( Sall4b \), the two \( Sall4 \) isoforms, were constitutively expressed in pediatric ALL patients as well as in normal control subjects, although there was no statistically significant difference in these values between pediatric ALL samples and normal control samples. Similar to \( Bmi-1 \), \( Sall4 \) expression has been reported in numerous hematological malignancies, including myelodysplastic syndromes [48], AML [49, 50], chronic myelogenous leukemia [51] and precursor B cell lymphoblastic lymphoma [52, 53]. In addition, we found that the \( Bmi-1 \) gene expression levels showed a significantly positive correlation with \( Sall4a \) but not \( Sall4b \). This result further verified the conclusion that a relationship between the \( Bmi-1 \) and \( Sall4 \) expression level in hematological malignancies, which was coincide with previously reports in AML samples [30, 31]. In addition, these findings indicate that \( Sall4a \) and \( Sall4b \) may have different functions in pediatric ALL. However, one would expect that \( Sall4a \) expression would be higher in primary ALL cells, but this was not the case in our study. We speculate that this discrepancy could be due to the weak correlation between \( Bmi-1 \) and \( Sall4a \) expression (\( r = 0.2707 \)) and additional factors involved in the complex regulation of \( Bmi-1 \) expression. In addition, \( Sall4a \) expression was slightly higher in primary ALL cells, but this increase was not significant. \( Sall4a \) is upstream of \( Bmi-1 \), and little difference was observed between individuals because of the amplification of the downstream signaling cascade. To better clarify this effect, more experiments with a larger cohort are needed. However, the precise molecular mechanism of \( Bmi-1 \) in pediatric ALL still remains unclear and requires further elucidation.

**Conclusion**

In summary, we provided evidence that \( Bmi-1 \) was significantly upregulated in pediatric ALL and that \( Bmi-1 \) overexpression was associated with a poor response to prednisone and a higher clinical risk. In addition, a significantly poorer outcome was observed in patients in the high \( Bmi-1 \) expression group. These findings suggest that \( Bmi-1 \) is an effective biomarker for predicting the prognosis of patients with pediatric ALL, and future studies should explore whether \( Bmi-1 \) could be a potential therapeutic target as well.

**Additional files**

- **Additional file 1: Table S1.** Detailed demographic characteristics of pediatric patients with ALL (\( n = 85 \)). (XLSX 15 kb)
- **Additional file 2: Table S2.** The demographic characteristics of healthy donors (\( n = 18 \)). (DOCX 16 kb)
- **Additional file 3: Table S3.** Sequences of the PCR primers and TaqMan probes. (DOCX 16 kb)
- **Additional file 4: Figure S1.** The expression levels of \( Bmi-1 \) in pediatric ALL patients who achieved CR versus normal control subjects (\( n = 18 \)). **(A) The average expression levels of \( Sall4a \) in pediatric ALL patients (\( n = 85 \)) versus that in normal control subjects (\( n = 18 \)), \( P = 0.0783 \). (B) The average expression level of \( Sall4b \) in pediatric ALL patients (\( n = 85 \)) versus that in normal control subjects (\( n = 18 \)), \( P = 0.2935 \). (C) The average expression levels of \( Sall4a \) before and after therapy (\( n = 19 \)) in the paired samples from pediatric ALL patients, (TIF 3 MB)
- **Additional file 5: Table S4.** Details of treatment regimens for patients with pediatric ALL. (DOCX 20 kb)
- **Additional file 6: Table S5.** Characteristics of the analyzed pediatric ALL subgroup. (DOCX 16 kb)
- **Additional file 7: Figure S2.** The expression levels of \( Sall4 \) in pediatric ALL clinical specimens. (A) The average expression levels of \( Sall4a \) in pediatric ALL patients (\( n = 85 \)) versus that in normal control subjects (\( n = 18 \)), \( P = 0.0783 \). (B) The average expression level of \( Sall4b \) in pediatric ALL patients (\( n = 85 \)) versus that in normal control subjects (\( n = 18 \)), \( P = 0.2935 \). (C) The average expression levels of \( Sall4a \) before and after therapy (\( n = 19 \)) in the paired samples from pediatric ALL patients.
All written informed consent was obtained from the participants. The authors declare that they have no competing interests. All data generated or analyzed during this study are included either in this article or in the supplementary information files. The work was supported by a National Nature and Science Grant of China (No. 81272310) and the Natural Science Foundation of Guangdong Province, China (2015A030313769).

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from each patient for the publication of this research. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
All written informed consent was obtained from the participants' parents or guardians. The research protocols were approved by the Ethics Committee of Guangzhou Women and Children's Medical Center and the First Affiliated Hospital of Sun Yat-sen University.

Author details
1. Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510623, China. 2. Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. 3. Department of Pediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 4. Department of Pediatrics, Zhuhou Central Hospital, Zhuhou, China.

Received: 29 January 2016 Accepted: 9 January 2017
Published online: 25 January 2017

References
1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52.
2. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol. 2008;9(9):832–7.
3. Bhogwani J, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205–17.
4. Hauy L, Alexander WS, Barl G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice. Cell. 1991;65(5):753–63.
5. van Loohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Bemis A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell. 1991;65(5):737–52.
6. Berger R, Baranger L, Bernheim A, Valensi F, Flandrin G. Cytogenetics of T-cell malignant lymphoma. Report of 17 cases and review of the chromosomal breakpoints. Cancer Genet Cytogenet. 1988;36(1):23–30.
7. Alkema MJ, Wiegant J, Raap AK, Bemis A, van Loohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet. 1993;2(10):1597–603.
8. Pui CH, Raimondi SC, Murphy SB, Ribeiro RC, Kalwinsky DK, DaHai GV, Cist WM, Williams DL. An analysis of leukemic cell chromosomal features in infants. Blood. 1987;69(5):1289–93.
9. Lessard J, Sauvageau G. BMI-1 determines the proliferative capacity of normal and leukemic stem cells. Nature. 2003;423(6937):255–60.
10. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. BMI-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003;425(6961):962–7.
11. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. BMI-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423(6937):302–5.
12. Facchino S, Abduou M, Chatou W, Bernier G. BMI-1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010;30(30):10096–111.
13. Ismail IH, Andrin C, McDonald D, Hendzel MJ. BMI-1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol. 2010;191(1):45–60.
14. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O, van Loohuizen M. BMI-1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007;12(4):528–41.
15. Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, Hornfeld D, Jaquet M, Munier FL, Schroeter DF, van Loohuizen M, et al. BMI-1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci. 2005;25(24):5774–83.
16. D'Mauro T, Cantor DJ, Bainer AJ, David G. Transcriptional repression of Sin3B by BMI-1 prevents cellular senescence and is relieved by oncogene activation. Oncogene. 2015;34(30):4011–7.
17. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Loohuizen M, Betticher DC. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84(10):1372.
18. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo HC, Lee Y, Choe IS, Kim JW. Overexpression of BMI-1 oncprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004;13(5):381–8.
19. Honig A, Weidler C, Hausler S, Krockenberger M, Buchholz S, Koster F, Segerer SE, Dietl J, Engel JB. Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res. 2010;30(5):1559–64.
20. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The BMI-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004;203(2):217–24.
21. Bea S, Fort T, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez P, van Loohuizen M, Colomer D, Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61(6):2409–12.
22. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ, Koenderink J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97(12):3896–901.
23. Sawia M, Yamamoto M, Yoshikawa S, Araki S, Hoshida A, Kajiguchi T, Seto M, Kohno A, Kitamura K, Itoh Y, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005;82(1):142–7.
24. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MX, Zha YF, et al. BMI-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006;66(18):9225–32.
25. van Leenders GJ, Dukers D, Hesse D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Meijer CJ, Koenderink J. BMI-1 expression is overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 2007;52(2):455–63.
26. Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Eaton D, Kote-Jarai Z, et al. Effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,846 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015;26(11):1603–16.

27. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Enaife R, Keyvanfar K, Kurlander R, Revzani K, Barrett AJ. Improved outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia. 2011;25(4):629–636.

28. Mohy M, Szydlo RM, Yong AS, Appelrey JF, Goldman JM, Melo JV. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. Blood. 2008;112(5):2163–6.

29. van Galen JC, Muris JJ, Oudejans JJ, Ves W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol. 2007;60(2):167–72.

30. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC, Ma Y. BMI-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A. 2007;104(25):10494–9.

31. Shen Q, Liu S, Hu J, Chen S, Yang L, Li B, Wu X, Ma Y, Yang J, Ma Y, et al. The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia. Cancer Cell Int. 2012;12(1):42.

32. Chen S, Liu S, Xu L, Yang L, Jin Z, Ma Y, Li B, Wu X, Yang J, Ma Y, et al. The characteristic expression pattern of BMI-1, SALL4 and ABCA3 genes in placenta tissue and cord blood. Stem Cell Res Ther. 2013;4(2):49.

33. Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH, Asian Oncology S. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 2013;14(12):e508–23.

34. Renes Troche JM, Chavez Barrera JA, Gonzalez Ortiz B, Heller Rouassant S, Montijo Barrios E, Velasco Lavin Mdel R, Worona Dibner LB, Association Mexicana de G. Guidelines for diagnosis and treatment of constipation in Mexico. D) Evaluation and treatment of constipation in pediatric population. Rev Gastroenterol Mex. 2011;76(2):155–68.

35. Yang GF, He WP, Ca MY, He LR, Luo JH, Deng HK, Guan XY, Zeng MS, Zeng YX, Xie D. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer. 2010;10:133.

36. Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg. 2012;36(5):1189–94.

37. Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, Lee SJ, Kong G, Lee JE, Kim JS, et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009;113(1):83–93.

38. Long Q, Liu L, Xia Y, Bai Q, Wang J, Yu J, Guo J. High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma. Tumour Biol. 2015;36(10):8007–14.

39. Yu D, Liu Y, Yang J, Jin C, Zhao X, Cheng J, Liu X, Qi X. Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma. Cell Biochem Biophys. 2015;71(1):261–9.

40. Tong YQ, Liu B, Zheng HY, He YJ, Gu J, Li F, Li Y. Overexpression of BMI-1 is associated with poor prognosis in cervical cancer. Asia Pac J Clin Oncol. 2012;8(4):e55–62.

41. Choy B, Bandla S, Xia Y, Tan D, Pennathur A, Luketich JD, Godfrey TE, Peters JH, Sun J, Zhou Z. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol. 2012;12:146.

42. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in myeloid leukemia. Cancer Cell Int. 2012;12(1):42.

43. Kajiume T, Ishikawa N, Ohno N, Sera Y, Karakawa S, Kobayashi M. Expression of the polycomb group gene Bmi-1 does not affect the prognosis of pediatric acute lymphoblastic leukemia. Stem Cell Discovery. 2012;02(02):25–30.

44. Clark JK, Morrison SJ, Clarke MF, Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004;113(2):175–9.

45. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beelke R, Kurlander R, Rezvani K, Barrett AJ. Improved outcome following allogeneic stem cell transplantation from HLA-identical siblings in acute myeloid leukemia. Cancer Causes Control. 2015;26(11):1603–16.

46. Amsterdam A, Tajima K, Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol. 2002;64(5–6):843–50.

47. Bose R, Moors M, Tofighi R, Cascante A, Hermanson O, Ceccatelli S. Glucocorticoids induce long-lasting effects in neural stem cells resulting in senescence-related alterations. Cell Death Dis. 2010;1:e92.

48. Wang F, Guo Y, Chen Q, Yang Z, Ning N, Zhang Y, Xu Y, Xu X, Tong C, Chai L, et al. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. J Hematol Oncol. 2013;6(1):73.

49. Ma JC, Qian J, Lin J, Qian W, Yang J, Wang CZ, Chai HY, Li Y, Chen Q, Qian Z. Aberrant hypomethylation of SALL4 gene is associated with intermediate and poor karyotypes in acute myeloid leukemia. Clin Biochem. 2013;46(4–5):304–7.

50. Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritjz J, Krause DS, Chai L. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006;108(8):2726–35.

51. Lu J, Ma Y, Kang N, Alipio Z, Gao C, Krause DS, Silberstein LE, Chai L. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia. 2011;25(7):1211–3.

52. Ueno S, Lu J, He J, Li A, Zhang X, Ritjz J, Silberstein LE, Chai L. Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target. Exp Hematol. 2014;42(4):307–16. e308.

53. Cui W, Kang NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol. 2006;19(12):1585–92.